Comparative Pharmacology
Head-to-head clinical analysis: FUNDUSCEIN 25 versus MACRILEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNDUSCEIN 25 versus MACRILEN.
FUNDUSCEIN-25 vs MACRILEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium absorbs blue light (465–490 nm) and emits yellow-green fluorescence (520–530 nm), allowing visualization of retinal and choroidal vasculature. It binds to serum proteins and leaks from abnormal blood vessels, highlighting areas of neovascularization or edema.
MACRILEN (macimorelin) is a synthetic growth hormone secretagogue receptor (GHS-R) agonist that stimulates growth hormone (GH) release from the anterior pituitary. It mimics the action of ghrelin, enhancing GH secretion through GHS-R activation.
0.5 mL of FUNDUSCEIN-25 (25 mg/mL) administered intravenously as a single bolus injection over 5-10 seconds.
1 mg subcutaneously once daily, titrated as needed to a maximum of 2 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 26 minutes in adults (range 20–30 minutes). Clinical context: Rapid clearance allows repeated injections within 30–60 minutes if needed.
Terminal elimination half-life is approximately 3 hours (range 2.5–4.5 hours) in healthy adults. This short half-life supports its use for diagnostic testing, with rapid clearance after stimulation of growth hormone release.
Primarily renal elimination of unchanged fluorescein and its glucuronide conjugate (80% within 24 hours). Biliary/fecal excretion accounts for <5%.
Primarily renal; approximately 90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized, with metabolites also eliminated renally. Fecal excretion is negligible (<2%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent